Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, Youyi Fong, David Benkeser, Weiping Deng, Haiyu Zhou, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Britta Flach, Bob C. Lin, Sarah O’Connell, Charlene McDanal, Amanda Eaton, Marcella Sarzotti‐Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, Chuong Huynh, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden, Mira Baron, Luis de la Cruz‐Merino, Cynthia L. Gay, Spyros A. Kalams, Colleen F. Kelley, Mark E Kutner, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Lindsay N. Carpp, Rolando Pajón, Dean Follmann, Rubén O. Donis, Richard A. KoupmedRxiv 2021 · DOI

TL;DR

This study investigated the relationship between antibody levels after mRNA-1273 COVID-19 vaccination and protection against infection. It found that higher levels of both binding and neutralizing antibodies were strongly associated with a lower risk of COVID-19 and higher vaccine efficacy, suggesting these antibodies can serve as reliable predictors of protection.

What Problem Does This Paper Address?

Developing effective vaccines against rapidly evolving pathogens like SARS-CoV-2 is crucial. A key challenge is understanding how vaccines work at a molecular level and identifying reliable "correlates of protection" – measurable biological indicators that predict whether a vaccine will be effective. These correlates are vital for accelerating vaccine development, regulatory approval, and for understanding how to adapt vaccines against new variants or for different populations. This paper addresses the need to establish such correlates for the mRNA-1273 vaccine by analyzing the relationship between various antibody responses and subsequent COVID-19 risk and vaccine efficacy.

Methods

The researchers employed a case-cohort sampling design within the COVE trial data. They measured four key serum antibody markers in a subset of participants: IgG binding antibodies (bAbs) to the Spike protein, bAbs to the Spike receptor-binding domain (RBD), and 50% and 80% inhibitory dilution pseudovirus neutralizing antibody titers (cID50 and cID80), all calibrated to WHO standards. These measurements were taken at different time points after vaccination (Day 1, Day 29, and Day 57). Statistical analyses, primarily Cox regression, were used to assess the association between these antibody levels and the risk of COVID-19 infection over time, adjusting for known risk factors. Causal mediation analysis was also used to quantify how much of the vaccine's protective effect was mediated by these antibody responses.

Datasets

The study utilized data from the Coronavirus Efficacy (COVE) phase 3 trial of the mRNA-1273 COVID-19 vaccine. This trial involved over 30,000 participants randomized to receive either the mRNA-1273 vaccine or a placebo. The analysis focused on participants with no prior SARS-CoV-2 infection.

Key Insights and Ideas

  • Antibodies as Predictors: The study strongly reinforces the idea that antibody levels are not just a byproduct of vaccination but are direct predictors of protection. This is a fundamental concept in vaccinology, but this study provides robust quantitative evidence for the mRNA-1273 vaccine.
  • Neutralizing Antibodies are Key: While binding antibodies are important, the neutralizing antibody titers (cID50 and cID80) showed a particularly strong inverse correlation with COVID-19 risk and a direct correlation with vaccine efficacy. This highlights the functional importance of antibodies that can block viral entry.
  • Early vs. Late Antibody Levels: The study found that antibody levels measured at Day 29 (after the second dose) correlated with COVID-19 risk as strongly as those measured later at Day 57. This suggests that earlier measurements might be sufficient for predicting protection, potentially simplifying future trial designs.
  • Mediation of Vaccine Efficacy: A significant portion (estimated at 68.5%) of the vaccine's overall efficacy was found to be mediated by Day 29 neutralizing antibody titers. This provides a mechanistic link between antibody response and protection.

Key Results

  • Inverse Correlation with Risk: For every 10-fold increase in antibody levels at Day 57, the hazard ratio for COVID-19 decreased significantly. For example, the hazard ratio for cID50 was 0.42, meaning a 10-fold increase in titer was associated with a 58% reduction in risk. Similar strong inverse correlations were observed for Spike IgG, RBD IgG, and cID80.
  • Dose-Response Relationship: Vaccine recipients with undetectable Day 57 cID50 titers had a cumulative incidence of COVID-19 of 3.0%, which dropped to 0.56% for those with titers of 100 and 0.23% for those with titers of 1000.
  • Vaccine Efficacy by Titer Level: Vaccine efficacy increased substantially with higher antibody titers. For instance, at undetectable cID50 titers, vaccine efficacy was around 50.8%, but it rose to 90.7% at a titer of 100 and 96.1% at a titer of 1000.
  • Mediation of Efficacy: Approximately 68.5% of the vaccine efficacy was estimated to be mediated by Day 29 cID50 titers.

Limitations and Future Work

  • Limited Scope of Outcomes: The study focused on symptomatic COVID-19 and did not assess correlates for other outcomes like severe disease, asymptomatic infection, or viral shedding.
  • Single Dose Recipients: The analysis did not include data from participants who received only one dose of the vaccine.
  • Viral Variants: The study was conducted when the ancestral SARS-CoV-2 strain was dominant. Therefore, the robustness of these correlates against newer variants with different spike proteins could not be assessed.
  • Future Work: The authors suggest future analyses should investigate antibody dynamics over longer periods to understand waning immunity and how efficacy relates to new variants. They also propose exploring correlates for vaccines from different platforms and the potential for using earlier antibody measurements (Day 29) as a surrogate marker for protection.

Summary updated

Abstract

Abstract Background In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection. Methods Through case-cohort sampling, participants were selected for measurement of four serum antibody markers at Day 1 (first dose), Day 29 (second dose), and Day 57: IgG binding antibodies (bAbs) to Spike, bAbs to Spike receptor-binding domain (RBD), and 50% and 80% inhibitory dilution pseudovirus neutralizing antibody titers calibrated to the WHO International Standard (cID50 and cID80). Participants with no evidence of previous SARS-CoV-2 infection were included. Cox regression assessed in vaccine recipients the association of each Day 29 or 57 serologic marker with COVID-19 through 126 or 100 days of follow-up, respectively, adjusting for risk factors. Results Day 57 Spike IgG, RBD IgG, cID50, and cID80 neutralization levels were each inversely correlated with risk of COVID-19: hazard ratios 0.66 (95% CI 0.50, 0.88; p=0.005); 0.57 (0.40, 0.82; p=0.002); 0.42 (0.27, 0.65; p<0.001); 0.35 (0.20, 0.61; p<0.001) per 10-fold increase in marker level, respectively, multiplicity adjusted P-values 0.003-0.010. Results were similar for Day 29 markers (multiplicity adjusted P-values <0.001-0.003). For vaccine recipients with Day 57 reciprocal cID50 neutralization titers that were undetectable (<2.42), 100, or 1000, respectively, cumulative incidence of COVID-19 through 100 days post Day 57 was 0.030 (0.010, 0.093), 0.0056 (0.0039, 0.0080), and 0.0023 (0.0013, 0.0036). For vaccine recipients at these titer levels, respectively, vaccine efficacy was 50.8% (−51.2, 83.0%), 90.7% (86.7, 93.6%), and 96.1% (94.0, 97.8%). Causal mediation analysis estimated that the proportion of vaccine efficacy mediated through Day 29 cID50 titer was 68.5% (58.5, 78.4%). Conclusions Binding and neutralizing antibodies correlated with COVID-19 risk and vaccine efficacy and likely have utility in predicting mRNA-1273 vaccine efficacy against COVID-19. Trial registration number COVE ClinicalTrials.gov number, NCT04470427
BibTeX
@misc{gilbert2021immune,
  author = {Peter B. Gilbert and David C. Montefiori and Adrian B. McDermott and Youyi Fong and David Benkeser and Weiping Deng and Haiyu Zhou and Christopher R. Houchens and Karen Martins and Lakshmi Jayashankar and Flora Castellino and Britta Flach and Bob C. Lin and Sarah O’Connell and Charlene McDanal and Amanda Eaton and Marcella Sarzotti‐Kelsoe and Yiwen Lu and Chenchen Yu and Bhavesh Borate and Lars W. P. van der Laan and Nima S. Hejazi and Chuong Huynh and Jacqueline M. Miller and Hana M. El Sahly and Lindsey R. Baden and Mira Baron and Luis de la Cruz‐Merino and Cynthia L. Gay and Spyros A. Kalams and Colleen F. Kelley and Mark E Kutner and Michele P. Andrasik and James G. Kublin and Lawrence Corey and Kathleen M. Neuzil and Lindsay N. Carpp and Rolando Pajón and Dean Follmann and Rubén O. Donis and Richard A. Koup},
  title = {{Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial}},
  year = {2021},
  doi = {10.1101/2021.08.09.21261290},
  howpublished = {medRxiv},
}
Figure